Aurinia Pharmaceuticals Reports New Phase IIb Data

Shares of Aurinia Pharmaceuticals Inc. were up over 5% in pre-market trading after it reported new remission data from its phase IIB AURA-LV (AURA) study in lupus nephritis (LN)

The company said the data demonstrated that over the course of the 48-week trial, patients on voclosporin stayed in remission approximately twice as long as those in the control group. It said the differences were statistically significant versus the control arm, and that duration of remission as measured by proteinuria is clinically meaningful as it may correlate with lower rates of progression to Chronic Kidney Disease. “Not only have more patients on voclosporin achieved complete remission, but they have done so faster,” said Vladimir Dobronravov, a clinical investigator for the study. “Patients on low-dose voclosporin are also maintaining remission for a longer duration–nearly twice that of the control group on average.”

Leave a Comment